



Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing

Chair's invitation

On behalf of the faculty, I am pleased to invite you to access the on-demand Pfizer Oncology Satellite Symposium **Treatment considerations in biomarker-driven NSCLC: Diagnostics and sequencing**. This pre-recorded session can be accessed on-demand from 14th – 29th September. In addition, we look forward to having you at our live 30-minute Q&A session with all members of the faculty. This will be held on **Tuesday 22nd September at 15.30–16.00 CET**.

Biomarker-driven advanced NSCLC continues to be a dynamic and rapidly changing field. Physicians need to integrate an ever-increasing amount of information to guide their treatment decisions and effectively manage their patients. During the symposium, our distinguished faculty will:

- Discuss recent and upcoming developments in the biomarker-driven aNSCLC field
- Review current treatment options across biomarker-driven aNSCLC to support appropriate treatment decisions and effective ongoing therapy management
- Share expert opinion on the integration of new diagnostic tools, such as liquid biopsy, for patient diagnosis and monitoring and the opportunities these provide in improving patient care

My colleagues and I encourage you to take advantage of this virtual setting opportunity to watch the recording at a time that suits you and also look forward to welcoming you to the live Q&A to discuss the session together.

Rosario García Campelo, Chair

Servicio de Oncología Médica, Hospital Universitario A Coruña, Spain

On-demand symposium

Chair: **Rosario García Campelo (Spain)**

5 mins	Welcome and introduction	Rosario García Campelo (Spain)
10 mins	Latest updates in molecular testing in NSCLC	Justin Gainor (USA)
10 mins	EGFR+ NSCLC: A personalised sequencing approach	Jesús Corral (Spain)
10 mins	ALK+ and ROS1+ NSCLC: Optimising patient outcomes	Todd Bauer (USA)

Live Q&A

Additionally, a live Q&A session with all faculty members to discuss the programme will be held on **Tuesday 22nd September at 15.30–16.00 CET**.



This meeting is organised and funded by Pfizer.
© 2020 Pfizer Pharma GmbH. All rights reserved.
August 2020. PP-ONC-GLB-0241